Paclitaxel-Induced Pneumonitis in Trinidad: A Case Report.
breast cancer
drug-induced
hypersensitivity
paclitaxel
pneumonitis
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
06
07
2022
entrez:
11
8
2022
pubmed:
12
8
2022
medline:
12
8
2022
Statut:
epublish
Résumé
Paclitaxel-induced pneumonitis (PIP) is an immune-mediated disease resulting from a delayed hypersensitivity reaction (type IV) to paclitaxel, an anti-microtubule chemotherapeutic drug commonly used to treat breast cancer in both neoadjuvant and adjuvant settings. PIP is diagnosed by exclusion utilizing laboratory work-up, imaging, biopsy studies, and results of antibiotic therapy because there is no single diagnostic test. Ground-glass opacifications on CT, coupled with minimal restrictive disturbance with decreased diffusion on pulmonary function tests (PFTs), negative bronchoalveolar lavage (BAL), and bronchoscopy cultures, may assist physicians in diagnosing paclitaxel-induced pneumonitis. In this report, we describe a case of PIP present in Trinidad, West Indies, which has not been described previously in this region.
Identifiants
pubmed: 35949737
doi: 10.7759/cureus.26613
pmc: PMC9357421
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e26613Informations de copyright
Copyright © 2022, Mohan et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Chemother. 2017 Apr;29(2):113-117
pubmed: 25978147
Mol Clin Oncol. 2017 Oct;7(4):677-680
pubmed: 29046799
Acta Oncol. 2013 Jun;52(5):1034-8
pubmed: 23244676
J Cancer Res Ther. 2021 Jan-Mar;17(1):262-265
pubmed: 33723166
Chest. 2008 Feb;133(2):528-38
pubmed: 18252919
Sci Rep. 2015 Aug 10;5:12977
pubmed: 26256764
Lung India. 2022 Mar-Apr;39(2):158-168
pubmed: 35259799
Front Oncol. 2021 Jun 23;11:701424
pubmed: 34249762